BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $PRAX readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07010471-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~EMERALD readout (P3) · Praxis Precision Medicines $PRAX
DESCRIPTION:A Clinical Trial for Participants With DEE to Assess Efficacy\,
  Safety\, Tolerability\, and PK of Relutrigine\n\nPrimary completion date:
  2026-12 (estimated) — month only\, shown on the 1st\nOriginally planned
 : 2026-04 (+8.0 months)\nPhase 3 · Neuro · Developmental and Epileptic E
 ncephalopathy 1\nEnrollment: 160 · Sites: 11\n\nPrimary completion = last
  participant's primary-endpoint data collected\; topline results usually f
 ollow weeks to months later. Sponsor-reported\, often an estimate. Not inv
 estment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07010471\nhttp
 s://clinicaltrials.gov/study/NCT07010471
URL:https://datacutoff.com/radar.html?nct=NCT07010471
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07019922-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~1mg elsunersen readout (P3) · Praxis Precision Medicines $PRAX
DESCRIPTION:A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess
  Efficacy and Safety\n\nPrimary completion date: 2026-12 (estimated) — m
 onth only\, shown on the 1st\nOriginally planned: 2026-06 (+6.0 months)\nP
 hase 3 · Neuro · Epileptic Encephalopathy\, SCN2A Encephalopathy\nEnroll
 ment: 40 · Sites: 10\n\nPrimary completion = last participant's primary-e
 ndpoint data collected\; topline results usually follow weeks to months la
 ter. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps
 ://datacutoff.com/radar.html?nct=NCT07019922\nhttps://clinicaltrials.gov/s
 tudy/NCT07019922
URL:https://datacutoff.com/radar.html?nct=NCT07019922
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07505004-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:~POWER2 readout (P3) · Praxis Precision Medicines $PRAX
DESCRIPTION:Randomized Clinical Trial Evaluating the Efficacy and Safety of
  Vormatrigine in Adults With Focal Seizures\n\nPrimary completion date: 20
 27-01 (estimated) — month only\, shown on the 1st\nPhase 3 · Neuro · F
 ocal Epilepsy\nEnrollment: 300 · Sites: 7\n\nPrimary completion = last pa
 rticipant's primary-endpoint data collected\; topline results usually foll
 ow weeks to months later. Sponsor-reported\, often an estimate. Not invest
 ment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07505004\nhttps:/
 /clinicaltrials.gov/study/NCT07505004
URL:https://datacutoff.com/radar.html?nct=NCT07505004
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
